A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma

Clinical trial NCT02508467 · COMPLETED

Trial details

NCT number: NCT02508467
Sponsor: Blueprint Medicines Corporation
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Hepatocellular Carcinoma (HCC)

Start date: 2015-07-31
Primary completion: 2021-06-30
Enrollment: 146

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.